Is Limbrel a selective COX-2 Inhibitor?
No, Limbrel is NOT a selective COX-2 Inhibitor. More generally, Limbrel is not a drug. A selective COX-2 inhibitor strongly favors the inhibition of the COX-2 enzyme over COX-1, and may drastically decrease the levels of COX-2 enzyme activity in the body. This has been shown to be a contributing factor in higher rates of stroke and heart attack for certain COX-2 inhibitors. On the other hand, Limbrel inhibits COX-1 and COX-2 at a ratio of almost 1:1, a more balanced action while leaving the body with necessary levels of COX-2 enzyme that it needs to generate proper amounts of arachidonic acid (AA) metabolites to maintain normal body functions. In addition, Limbrel is the first and only prescription product to help nutritionally manage the 5-Lipoxygenase (5-LOX) pathway to reduce the production of Leukotriene B4 (LTB4), a potent chemoattractant molecule of white blood cells which can cause additional inflammation at the site of injury. Elevated LTB4 has been shown to contribute to gastr
